HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS- Vol. 22 • No. N1 • February 2020
In this issue:
-Writer's block due to pharmacokinetic interaction
Zullino D., and Penzenstadler L.
-Mood Stabilizing Effects of Methadone in Opioid Use Disorder Patient
Gohari J., and Riaz U.
-The impact of affective temperaments on opioid dependence and addiction severity
Inanli I., Ozturk H.I., Caliskan A.M., Ozbek S., Demirel B., Er M., and Eren I.
-Stigma against pregnant women addicted to opioids with a case report
Mehić-Basara N., Marjanović-Lisac S., and Grabovica M.
-High prevalence and risks factors for non-communicable diseases in older people with opioid use disorder.
Vallecillo G., Robles M.J., Duran X., Castillo C., Fonseca F., and Torrens M.
-Is the Treatment Long Enough? Associations Between Quality of Life and Treatment Duration in Methadone Maintenance Treatment
Chen Y.-A., Yen T.-T., Hsu W.-Y., Chang T.-G., Chang Y.-J., Chiu N.-Y., and Chang C.-C.
-Nearly thirty years of experience of real-world long-term treatment with Agonists Opioid Medications
Lamanna F., Maremmani A.G.I., and Maremmani I.
http://www.heroinaddictionrelatedclinicalproblems.org/harcp-archives.php?year=2020
Buprenorphine–cannabis interaction in patients undergoing opioid maintenance therapy
Vierke, C., Marxen, B., Boettcher, M. et al.
Eur Arch Psychiatry Clin Neurosci (2020). doi.org/10.1007/s00406-019-01091-0
https://link.springer.com/article/10.1007%2Fs00406-019-01091-0
High prevalence of hepatitis C virus infection and low level of awareness among people who recently started injecting drugs in a cross-sectional study in Germany, 2011–2014: missed opportunities for hepatitis C testing.
Enkelmann, J., Gassowski, M., Nielsen, S. et al.
Harm Reduct J 17, 7 (2020) doi:10.1186/s12954-019-0338-y
https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-019-0338-y
Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH).
Marcellin F, Di Beo V, Aumaitre H, Mora M, Wittkop L, Duvivier C, Protopopescu C, Lacombe K, Esterle L, Berenger C, Gilbert C, Bouchaud O, Poizot-Martin I, Sogni P, Salmon-Ceron D, Carrieri P; ANRS CO13 HEPAVIH Study Group.
J Hepatol. 2020 Jan 7. pii: S0168-8278(19)30646-4. doi: 10.1016/j.jhep.2019.10.019.
https://www.journal-of-hepatology.eu/article/S0168-8278(19)30646-4/fulltext
New psychoactive substances (NPS) in the Netherlands: occurrence in forensic drug samples, consumer drug samples and poisons center exposures between 2013 and 2017.
Hondebrink, L., Nugteren‐van Lonkhuyzen, J. J., Hunault, C. C., van den Berg, J., van der Gouwe, D., and van Riel, A. J. H. P. ( 2020)
Addiction,doi.org/10.1111/add.14868.
https://onlinelibrary.wiley.com/doi/full/10.1111/add.14868?campaign=wolearlyview
USA. Johns Hopkins Scientists Give Psychedelics the Serious Treatment
The first research center of its kind in the country is bringing renewed rigor to the investigation of the drugs’ therapeutic uses. (Scientific American, USA, 16.01.2020)
https://www.scientificamerican.com/article/johns-hopkins-scientists-give-psychedelics-the-serious-treatment/
Estimating the impact of drug use on US mortality, 1999-2016.
Glei DA, Preston SH (2020)
PLoS ONE 15(1): e0226732. doi.org/10.1371/journal.pone.0226732
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0226732
USA. Zahl der Toten durch E-Zigaretten in den USA auf 60 gestiegen
New York – Die Zahl der Toten nach dem Gebrauch von E-Zigaretten in den USA steigt weiter an. 60 Menschen seien bislang gestorben, teilte die US-Gesundheitsbehörde CDC heute mit. (aerzteblatt.de, 17.01.2020)
https://www.aerzteblatt.de/nachrichten/108735/Zahl-der-Toten-durch-E-Zigaretten-in-den-USA-auf-60-gestiegen
Drawing attention to a neglected injecting-related harm: a systematic review of AA amyloidosis among people who inject drugs.
Harris M, Brathwaite R, Scott J, Gilchrist G, Ciccarone D, Hope V, McGowan CR.
Addiction. 2018 Oct;113(10):1790-1801. doi: 10.1111/add.14257. Epub 2018 Jun 8.
https://researchonline.lshtm.ac.uk/id/eprint/4647495/
Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis.
Appiah-Kusi E, Petros N, Wilson R, Colizzi M, Bossong MG, Valmaggia L, Mondelli V, McGuire P, Bhattacharyya S.
Psychopharmacology (Berl). 2020 Jan 8. doi: 10.1007/s00213-019-05442-6.
https://link.springer.com/article/10.1007%2Fs00213-019-05442-6
Association Between Automotive Assembly Plant Closures and Opioid Overdose Mortality in the United States: A Difference-in-Differences Analysis.
Venkataramani AS, Bair EF, O’Brien RL, Tsai AC.
JAMA Intern Med. Published online December 30, 2019. doi:10.1001/jamainternmed.2019.5686
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2757788
Wechselwirkungen mit HCV-DAA-Medikamenten – Update on hep-druginteractions.org
We have added some new comedications to the interaction checker, at the request of some of our users. You can now look up interactions with alcohol, cannabidiol (CBD), carfentanil, clofazimine, heroin and mesna. (The University of Liverpool’s HEP Drug Interactions Checker, UK, 06.01.2020)
https://hep-druginteractions.org/checker
Gender and drug policy: Exploring global innovative approaches to drug policy and incarceration
Across the Americas, drug policies have failed to make a significant dent in the drug trade, while corruption and organized crime continue to thrive. At the same time, these harmful drug policies disproportionately fall on the most vulnerable, including poor women who often enter the drug trade because of desperation, lack of opportunity, and coercion. Stuck in a vicious cycle, the incarceration of these women only heightens their situation of vulnerability and takes a toll on their families and communities. (IDCP, UK, 2017-2020, Artikelserie)
https://idpc.net/publications/2017/06/gender-and-drug-policy-exploring-global-innovative-approaches-to-drug-policy-and-incarceration
Die neue Praxisleitlinie Substitutionsbehandlung bei Opioidfehlgebrauch in der Schmerztherapie (POM)
Die neue Praxisleitlinie Substitutionsbehandlung bei Opioidfehlgebrauch in der Schmerztherapie (POM)
Ein bis drei Prozent der Patienten mit einer Langzeitverordnung von Opioiden zur Schmerztherapie entwickeln einen „Fehlgebrauch“. Abhängigkeit und Suchtverhalten können die Folge sein. Die neue DGS-Praxisleitlinie „Substitutionsbehandlung bei Opioidfehlgebrauch in der Schmerztherapie“ widmet sich erstmalig diesem speziellen Problembereich.
Opioide haben per se ein Gewöhnungs- und Suchtpotenzial. Allerdings gibt es einen deutlichen Unterschied zwischen der physischen Abhängigkeit und Gewöhnung (Toleranz) und einer psychischen Abhängigkeit (Sucht). Die klinischen Zeichen einer Abhängigkeit und Sucht gehen mit einer Verhaltensänderung einher: Es steht nicht mehr die Schmerzlinderung bei der Einnahme des Opioids im Vordergrund, sondern das Erleben von Euphorie und das intensive, nicht zu unterdrückende Verlangen nach dem Opiat.
Bei Anzeichen von „Fehlgebrauch“ ist die Diagnose Prescription Opioid Misuse (POM) zu stellen. Steht die Diagnose POM und ist die Entscheidung zu einem Therapiewechsel gefallen, kann der Einsatz eines Substitutionsmittels erwogen werden. Zur Substitution stehen heutzutage mehrere Substanzen zur Auswahl, die ihrerseits als Opioide in der Schmerztherapie Verwendung finden, sich aufgrund ihrer langen Halbwertszeit und aus pharmakologischen Gründen aber auch für kontrollierte Substitutionsbehandlungen eignen.
VNR-Nummer 2760709118103510013
Zeitraum 15.08.2019 – 14.08.2020
Zertifiziert in D, A
Zertifiziert durch Akademie für Ärztliche Fortbildung, Rheinland Palz
CME-Punkte 2 Punkte (Kategorie D)
https://www.cme-kurs.de/kurse/praxisleitlinie-substitutionsbehandlung-opioidfehlgebrauch-schmerztherapie
Maternal prescribed opioid analgesic use during pregnancy and associations with adverse birth outcomes: A population-based study.
Sujan AC, Quinn PD, Rickert ME, Wiggs KK, Lichtenstein P, Larsson H, et al. (2019)
PLoS Med 16(12): e1002980. doi.org/10.1371/journal.pmed.1002980
https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002980
Misuse of fentanyl and fentanyl analogues
This report advises government on the number and nature of known fentanyl analogues, risk factors, pharmacology, toxic effects and misuse and associated harms. (Advisory Council on the Misuse of Drugs, UK, 03.01.2020)
https://www.gov.uk/government/publications/misuse-of-fentanyl-and-fentanyl-analogues
Pain sensitivity and analgesic use among 10,486 adults: the Tromsø study.
Samuelsen PJ, Nielsen CS, Wilsgaard T, Stubhaug A, Svendsen K, Eggen AE.
BMC Pharmacol Toxicol. 2017 Jun 9;18(1):45. doi: 10.1186/s40360-017-0149-2.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5466805/
The Association of Memory Disorders and Chronic HIV Disease in the Antiretroviral Therapy Era - A Systematic Literature Review
E Ripamonti; M Clerici
HIV Medicine. 2020;21(1):9-20.
https://www.medscape.com/viewarticle/922726
HIV prevalence among people who inject drugs (PWID) and related factors in Iran: a systematic review, meta‐analysis and trend analysis.
Rahimi, J., Gholami, J., Amin‐Esmaeili, M., Fotouhi, A., Rafiemanesh, H., Shadloo, B., and Rahimi‐Movaghar, A. ( 2020)
Addiction, doi.org/10.1111/add.14853.
Abstract
https://onlinelibrary.wiley.com/doi/abs/10.1111/add.14853?campaign=wolearlyview
International Journal of Drug Policy
Volume 75, January 2020
https://www.sciencedirect.com/journal/international-journal-of-drug-policy/vol/75/suppl/C
Rauchstoppversuche und genutzte Entwöhnungsmethoden
Eine deutschlandweite repräsentative Befragung anhand sozioökonomischer Merkmale in 19 Wellen von 2016–2019 (DEBRA-Studie)
Smoking cessation attempts and common strategies employed—a Germany-wide representative survey conducted in 19 waves from 2016 to 2019 (The DEBRA Study) and analyzed by socioeconomic status
Kotz, Daniel; Batra, Anil; Kastaun, Sabrina
Dtsch Arztebl Int 2020; 117: 7-13; DOI: 10.3238/arztebl.2020.0007
https://www.aerzteblatt.de/archiv/211741
National, regional, and global burdens of disease from 2000 to 2016 attributable to alcohol use: a comparative risk assessment study
Shield, Kevin et al.
The Lancet Public Health, Volume 5, Issue 1, e51 - e61
https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(19)30231-2/fulltext
High‐ versus low‐intensity internet interventions for alcohol use disorders: results of a three‐armed randomized controlled superiority trial.
Sundström, C., Eék, N., Kraepelien, M., Fahlke, C., Gajecki, M., Jakobson, M., Beckman, M., Kaldo, V., and Berman, A. H. ( 2020)
Addiction, doi.org/10.1111/add.14871.
https://onlinelibrary.wiley.com/doi/full/10.1111/add.14871?campaign=wolearlyview
No excuses left to delay opioid agonist treatment roll-out.
Malyuta R, Krausz RM.
Lancet HIV. 2019 Dec 23. pii: S2352-3018(19)30409-6. doi: 10.1016/S2352-3018(19)30409-6.
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(19)30409-6/fulltext
The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada.
Piske, M., Zhou, C., Min, J. E., Hongdilokkul, N., Pearce, L. A., Homayra, F., Socias, E., McGowan, G., and Nosyk, B. ( 2020)
Addiction, doi.org/10.1111/add.14947.
Abstract
https://onlinelibrary.wiley.com/doi/abs/10.1111/add.14947?campaign=wolacceptedarticle
Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.
Malta M, Varatharajan T, Russell C, Pang M, Bonato S, Fischer B (2019)
PLoS Med 16(12): e1003002. https://doi.org/10.1371/journal.pmed.1003002
https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003002
Initiation of injectable opioid agonist treatment in hospital: A case report.
McAdam M, Brar R, Young S.
Drug Alcohol Rev. 2019 Dec 9. doi: 10.1111/dar.13020.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/31814186
Recurrent Use of Implantable Buprenorphine.
Campbell MC.
Prim Care Companion CNS Disord. 2019 Dec 5;21(6). pii: 19l02434. doi: 10.4088/PCC.19l02434.
https://www.psychiatrist.com/pcc/article/pages/2019/v21n06/19l02434.aspx
A Retrospective Survey of Buprenorphine Substitute Treatment With Minimal Dosage in Heroin Use Disorder.
Shen W, Wang Q, Zhang J, Ping W, Zhang J, Ye W, Hu Q, Cerci D, Zhou W.
Front Psychiatry. 2019 Dec 4;10:888. doi: 10.3389/fpsyt.2019.00888.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904327/
Depot Buprenorphine Injection In The Management Of Opioid Use Disorder: From Development To Implementation.
Ling W, Shoptaw S, Goodman-Meza D.
Subst Abuse Rehabil. 2019 Nov 29;10:69-78. doi: 10.2147/SAR.S155843.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889966/
Seite 1 von 8